

Project scope: Optune Gio® Tumour-Treating Field Therapy

March 2025

Research question(s)

1. In patients diagnosed with glioblastoma, IDH wildtype, what is the clinical effectiveness, cost effectiveness, and safety of Optune® Tumour-Treating Fields therapy in addition to current standard of care compared with current standard of care alone?
2. What is the experience and opinion of patients who have chosen treatment with Optune® Tumour-Treating Fields therapy?

Inclusion criteria

The selection of studies for inclusion in the literature review element of the project will be based on the following criteria:

Population	<ul style="list-style-type: none"> People with newly diagnosed glioblastoma, IDH-wildtype (WHO Grade 4 glioma) following maximal debulking surgery or biopsy, radiation and or chemotherapy, concomitant with maintenance Temozolomide after systemic therapy stopped.
Intervention	<ul style="list-style-type: none"> Optune® Tumour-Treating Fields therapy <p><i>The therapy is designed to complement current standard of care, rather than replace any existing interventions. TTFIELDS therapy is delivered via four transducer arrays and is recommended for at least 18 hours per day.</i></p>
Comparator	<ul style="list-style-type: none"> Current standard of care in NHSScotland
Outcomes	<ul style="list-style-type: none"> Progression-free survival Overall survival Overall response rate Health-related quality of life Adverse events
Setting	<ul style="list-style-type: none"> Any setting where the standard of care provided to patients with WHO Grade 4 glioma aligns with that offered by NHSScotland
Limits	<ul style="list-style-type: none"> English language only

Exclusion criteria

The exclusion of studies from the literature review element of the project will be based on the following criteria:

Population	<ul style="list-style-type: none">■ People with <i>recurrent</i> glioblastoma■ People aged under 18 years
Intervention	<ul style="list-style-type: none">■ Studies in which the standard of care does not match the standard of care in NHSScotland
Comparator	-
Outcomes	-
Setting	-
Limits	<ul style="list-style-type: none">■ Studies not in English

Planned activities

SHTG have agreed on the following activities to support the development of an SHTG Innovative Medical Technology Overview (IMTO) on Optune® Tumour-Treating Fields therapy:

- An evidence review of the published literature on clinical effectiveness, cost effectiveness, safety and patient experience.

End products

At the end of the project, SHTG will publish:

- SHTG IMTO

Timescales (approximate)

Publication in September 2025.